Nuvation Bio Past Earnings Performance
Past criteria checks 0/6
Nuvation Bio's earnings have been declining at an average annual rate of -29.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
-29.1%
Earnings growth rate
-19.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -12.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14
Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Revenue & Expenses BreakdownBeta
How Nuvation Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -76 | 29 | 71 |
| 30 Sep 23 | 0 | -83 | 30 | 66 |
| 30 Jun 23 | 0 | -90 | 31 | 68 |
| 31 Mar 23 | 0 | -105 | 32 | 79 |
| 31 Dec 22 | 0 | -104 | 32 | 88 |
| 30 Sep 22 | 0 | -108 | 32 | 89 |
| 30 Jun 22 | 0 | -103 | 30 | 85 |
| 31 Mar 22 | 0 | -88 | 27 | 70 |
| 31 Dec 21 | 0 | -87 | 24 | 65 |
| 30 Sep 21 | 0 | -75 | 21 | 56 |
| 30 Jun 21 | 0 | -64 | 18 | 48 |
| 31 Mar 21 | 0 | -53 | 14 | 41 |
| 31 Dec 20 | 0 | -42 | 11 | 33 |
| 30 Sep 20 | 0 | -38 | 8 | 32 |
| 30 Jun 20 | 0 | -32 | 7 | 27 |
| 31 Mar 20 | 0 | -33 | 7 | 26 |
| 31 Dec 19 | 0 | -34 | 7 | 25 |
Quality Earnings: NUVB is currently unprofitable.
Growing Profit Margin: NUVB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NUVB is unprofitable, and losses have increased over the past 5 years at a rate of 29.1% per year.
Accelerating Growth: Unable to compare NUVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NUVB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: NUVB has a negative Return on Equity (-12.53%), as it is currently unprofitable.